Communication, FDA and White Paper - Pharmacy Technician Pulse

Insmed wins FDA approval for future blockbuster Brinsupri

Pharmaceutical Technology

AUGUST 13, 2025

Buy Reports Newsletters PT News Insmed wins FDA approval for future blockbuster Brinsupri Brinsupri becomes the first bronchiectasis therapy while ushering in a new class of DPP1 inhibitors. Brinsupri has been approved to treat adults and children aged 12 years and over with NCFB. Give your business an edge with our leading industry insights.

FDA

FDA Packaging Communication Hospitals

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

Pharmaceutical Technology

JUNE 25, 2025

The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for adults with bullous pemphigoid (BP), a condition that predominantly affects the elderly. In February 2025, the FDA accepted Dupixent’s supplemental biologics licence application (sBLA) for priority review.

FDA

FDA Packaging Communication Hospitals

FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer

Pharmaceutical Technology

AUGUST 11, 2025

Buy Reports Newsletters PT News FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer Vepdegestrant is an investigational, oral bioavailable PROteolysis TArgeting Chimera (PROTAC) medication. Credit: Gorodenkoff/Shutterstock.com. Give your business an edge with our leading industry insights.

FDA

FDA Packaging Communication Hospitals

UK enacts law to decentralise manufacture of personalised treatments

Pharmaceutical Technology

JULY 23, 2025

The MHRA has recognised that some practices are better with more flexibility, and that in a technology-enabled world which allows better training, information and communication, flexibility can be enabled without compromising safety. We may still continue to send you service-related and other non-promotional communications.

Communication

Communication Hospitals Packaging Insurance

HCP Targeting in Pharma Marketing

Pharma Marketing Network

JUNE 16, 2025

HCPs now seek scientific, outcomes-based communication—not promotional fluff. Educational webinars, white papers, and digital reprints are performing well, especially when endorsed by credible experts. All messaging must also go through MLR (medical, legal, and regulatory) review to ensure it aligns with FDA guidelines.

HIPAA

HIPAA Communication Patient Care FDA

Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency

Pharmaceutical Technology

JULY 29, 2025

The US Food and Drug Administration (FDA) has granted approval for Ascendis Pharma’s Skytrofa (lonapegsomatropin-tcgd, developed as TransCon hGH), a prodrug of somatropin or human growth hormone (HGH), to treat adults with growth hormone deficiency (GHD). Credit: Andrei Kuzmik / Shutterstock.com.

FDA

FDA Packaging Labelling Communication

MSD receives FDA approval for Enflonsia to prevent RSV

Pharmaceutical Technology

JUNE 10, 2025

MSD has received US Food and Drug Administration (FDA) approval for Enflonsia (clesrovimab-cfor) to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants. Can pharma tariffs “Make America Manufacture Again”? Credit: MargJohnsonVA/Shutterstock.

FDA

FDA Research Laboratories Communication Hospitals

J&J seeks FDA approval for icotrokinra to treat psoriasis

Pharmaceutical Technology

JULY 22, 2025

Johnson & Johnson (J&J) has submitted a new drug application (NDA) seeking approval from the US Food and Drug Administration (FDA) for its oral peptide, icotrokinra, to treat moderate to severe plaque psoriasis (PsO) in adults and children aged 12 years and above. Credit: design_cam/Shutterstock.com.

FDA

FDA Immunization Packaging Communication

Amphastar and Anji make licence agreement for three new peptides

Pharmaceutical Technology

AUGUST 13, 2025

Subscribe Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Give your business an edge with our leading industry insights.

Insmed wins FDA approval for future blockbuster Brinsupri

FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid

Trending Sources

FDA gives Arvinas and Pfizer’s vepdegestrant NDA for breast cancer

UK enacts law to decentralise manufacture of personalised treatments

HCP Targeting in Pharma Marketing

Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency

MSD receives FDA approval for Enflonsia to prevent RSV

J&J seeks FDA approval for icotrokinra to treat psoriasis

Amphastar and Anji make licence agreement for three new peptides

MetrioPharm gains orphan drug status from EMA for MP1032

Vutrisiran marks first silencer approved for ATTR-CM

Fosun and Expedition make $645m licensing deal for respiratory drug

FDA approves YolTech’s YOLT-101 for familial hypercholesterolemia

Mosanna Therapeutics gains $80m to advance OSA nasal spray

Eli Lilly and GSK drive South Korea’s drug licensing activity

Tisento’s MELAS treatment receives fast track status from FDA

George Tidmarsh to sub in as FDA CBER head following Prasad’s shock exit

Alfasigma sets stage for Jyseleca in axSpA after Phase III win

Fangzhou and Novo Nordisk link on chronic disease management

European pharma needs scalable models to succeed in US

Sanofi concludes Blueprint Medicines acquisition

How ICH E6 (R3) is changing clinical trials

Sartorius to invest $3m for minority share in biotech start-up Nanotein

GSK’s Blenrep combos approved for multiple myeloma in EU

Janssen’s Darzalex new indication gains EC approval for SMM

AstraZeneca announces $50bn US investment plans by 2030

AbbVie expands North Chicago API production with $195m investment

Revolution Medicines partners Royalty Pharma on $2bn funding

Big pharma braces for revenue headwinds as patent expiries loom

FDA approves label updates for BMS’ CAR T cell therapies

Actio gains $66m to advance small molecule therapeutics pipeline

FDA approves KalVista’s Ekterly for hereditary angioedema

MAXONA Pharma seeks FDA approval for pain relief MAX-001

Piramal Pharma announces $90m investment to expand US sites

GE HealthCare’s PET imaging agent gains Alzheimer’s label expansion

EpiPen patent expiry opens new era for innovation

Madrigal poised to enter European MASH market after CHMP endorsement

EU’s Pharma Package falls short of Europe’s goal of global competitiveness

Targeting energy expenditure: the next wave of obesity drugs

Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics

FDA gives accelerated approval to Jazz Pharma’s diffuse midline glioma therapy

FDA gives TSND-201 breakthrough therapy designation for PTSD

NextCure and Simcere partner to develop SIM0505 for solid tumours

Vertex wins European approval for Alyftrek, bolstering cystic fibrosis stronghold

Stay Connected